-
Mashup Score: 4
Sam Chang hosts Vikram Narayan for a discussion on the potential of urinary markers in predicting responses to nadofaragene, a treatment for BCG-unresponsive bladder cancer. Dr. Narayan discusses findings from a study utilizing the UroAmp test for assessing urinary minimal residual disease (MRD) in patients treated with nadofaragene. This next-generation sequencing approach reveals the mutation…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 4
Sam Chang hosts Vikram Narayan for a discussion on the potential of urinary markers in predicting responses to nadofaragene, a treatment for BCG-unresponsive bladder cancer. Dr. Narayan discusses findings from a study utilizing the UroAmp test for assessing urinary minimal residual disease (MRD) in patients treated with nadofaragene. This next-generation sequencing approach reveals the mutation…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 2
Niyati Lobo joins Ashish Kamat in a conversation about the updated European Association of Urology (EAU) prognostic risk groups and whether or not the updates appropriately consider patients treated with BCG. Dr. Lobo discusses the applicability of the updated groups in a contemporary cohort of non-muscle-invasive bladder cancer (NMIBC) patients at MD Anderson treated with bacillus…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 3
Niyati Lobo joins Ashish Kamat in a conversation about the updated European Association of Urology (EAU) prognostic risk groups and whether or not the updates appropriately consider patients treated with BCG. Dr. Lobo discusses the applicability of the updated groups in a contemporary cohort of non-muscle-invasive bladder cancer (NMIBC) patients at MD Anderson treated with bacillus…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Niyati Lobo joins Ashish Kamat in a conversation about the updated European Association of Urology (EAU) prognostic risk groups and whether or not the updates appropriately consider patients treated with BCG. Dr. Lobo discusses the applicability of the updated groups in a contemporary cohort of non-muscle-invasive bladder cancer (NMIBC) patients at MD Anderson treated with bacillus…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
Urinary minimal residual disease detection predicts recurrence in BCG-unresponsive #NIMBC and quantifies molecular response to nadofaragene firadenovec. @VikramNarayan & @UroCancerMD discuss the potential of urinary markers in predicting responses > https://t.co/VbcD9S6WLl https://t.co/4HPo6TJ1Yl